Drägerwerk

The Drägerwerk preferred share is trading near its yearly high and sits well above the medium-term upward trend channel; the RSI signals slight overbought conditions. Fundamentally, the company is supported by two recent price-target increases, and a further raise was discussed internally. However, after a year-to-date gain of almost 70%, the stock would be vulnerable to a market correction or profit-taking. Technically, the medium-term trend currently runs roughly around €102 on the upside and around €83 on the downside. » Mais em finanzen.net

Stefan Dräger sees the German chemical sector in decline and speaks of a quiet crisis, because many production plants are shut down or not being restarted. As a supplier of measurement and safety equipment, Dräger is recording revenue declines in the chemical sector but can offset these through growth in other areas. Dräger cites energy prices and bureaucracy as the main reasons for the difficult situation. » Mais em finanzen.net

Drägerwerk has upgraded its full-year targets again in mid and late July, mainly thanks to customs refunds totaling around €22 million. The 2026 EBIT margin is now expected at 6–8% (previously 5.5–7.5%), while revenue growth remains unchanged at 1–5% (currency-adjusted 2–6%). In the first half, currency-adjusted revenue rose 7.7% to €1,603.2 million and EBIT increased to €63.8 million. Investors are speculating, due to the strong H1 figures, about a further target increase ahead of the Q3 results; the editorial team says the stock should be on the watchlist. » Mais em finanzen.net